| Literature DB >> 30622513 |
Young Sik Choi1,2, Ji Hyun Park2,3, Jae Hoon Lee1,2, Jeong-Kee Yoon4, Bo Hyon Yun1,2, Joo Hyun Park2,3, Seok Kyo Seo1,2, Hak-Joon Sung4, Hyun-Soo Kim5, SiHyun Cho2,3, Byung Seok Lee1,2.
Abstract
Background: Repair of DNA double strand break (DSB) is an important mechanism for maintaining genetic stability during a DNA damage event. Although, a growing body of recent evidence suggests that DNA DSBs and related repair mechanisms may be important in ovarian aging and in various cancers, there are few reports in endometriosis. We, therefore, examined expression levels of genes pertaining to DNA DSB repair in patients with endometriosis to assess the potential effects on ovarian reserves. Materials and methods: A total of 69 women undergoing laparoscopic surgery for endometriosis and other benign conditions was included; endometriosis group (n = 38) vs. controls (n = 31). DNA DSBs in endometrial and ovarian tissues of both groups were compared via immunohistochemistry, aimed at γ-H2AX expression. To gauge genotoxin-induced DNA DSBs in endometrial stromal cells, γ-H2AX expression was determined by western blot after H2O2 treatment of cultured endometrial stromal cells (endometriosis group and controls) and Ishikawa cell-line cultures. Endometrial and ovarian tissue levels of BRCA1, BRCA2, Rad51, and ATM (ataxia-telangiectasia mutated) mRNA expression were also compared. Correlations between expression levels of genes of interest and serum anti-müllerian hormone (AMH) levels were assessed as well.Entities:
Keywords: BRCA1 gene; double stranded DNA break; endometriosis; gamma-H2AX; ovarian reserve
Year: 2018 PMID: 30622513 PMCID: PMC6308303 DOI: 10.3389/fendo.2018.00772
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Clinical characteristics of study participants with and without endometriosis.
| Age (years) | 35.02 ± 1.22 | 36.64 ± 1.18 | 0.353 |
| Gravidity | 1.13 ± 0.23 | 2.16 ± 0.31 | 0.009 |
| Parity | 0.64 ± 0.15 | 1.35 ± 0.17 | 0.003 |
| BMI (kg/m2) | 20.47 ± 0.30 | 22.39 ± 0.44 | < 0.001 |
| CA-125 (U/mL) | 65.27 ± 8.28 | 19.03 ± 2.59 | < 0.001 |
| III | 18 (47.4%) | N/A | |
| IV | 20 (52.6%) | ||
| rAFS scores | 49.22 ± 25.57 | N/A | |
| Serum AMH (ng/mL) | 2.05 ± 0.40 | 4.97 ± 1.18 | 0.039 |
Data expressed as mean ± standard error mean (SEM) BMI, body mass index; EMS, endometriosis; rAFS, revised American Fertility Society; AMH, anti-Müllerian hormone.
Figure 1Expression levels of γ-H2AX protein in tissue samples of eutopic and ectopic endometrium of patients with and without endometriosis. (A) CTL-EM, eutopic endometrium of control group: γ-H2AX expression absent, or very faint in stromal cells; (B) EMS-EM, ectopic endometrium of endometriosis group: patchy γ-H2AX expression of variable staining intensity, most stromal cells showing moderate nuclear γ-H2AX immunoreactivity; (C) EMS-OV, ectopic endometrium of endometriosis group: stromal cells demonstrating uniform and strong γ-H2AX immunoreactivity (γ-H2AX expression by glandular epithelium similar in control and in endometriosis groups); and (D) CTL-OV, normal ovarian stroma: absence of γ-H2AX expression (original magnification: A–D, × 100; inset, × 400).
Figure 2Western blot analysis of γ-H2AX in cultured Ishikawa cell lines and in primary endometrial stromal cells of patients with and without endometriosis after H2O2 treatment. *p < 0.05. Data are expressed as mean ± SEM values. +, with H2O2 treatment; –, without H2O2 treatment; CTL-EM, eutopic endometrium of patients without endometriosis; EMS-EM, eutopic endometrium of patients with endometriosis.
Figure 3Endometrial mRNA expression of BRCA1, BRCA2, Rad51, and ATM in endometriosis group and in controls. *p < 0.05. Data are expressed as mean ± SEM.
Figure 4Ovarian mRNA expression of BRCA1, BRCA2, Rad51, and ATM in endometriosis group and in controls. *p < 0.05, **p < 0.01. Data are expressed as mean ± SEM.
Figure 5Correlation between serum anti-Müllerian hormone levels (AMH) and ovarian BRCA1 expression in patients with endometriosis (Spearman's rho, 0.541; p = 0.030).
Figure 6Immunofluorescence staining of BRCA1 in eutopic endometrium and ovarian tissue of patients with and without endometriosis. CTL-EM, eutopic endometrium of patients without endometriosis; EMS-EM, eutopic endometrium of patients with endometriosis; CTL-OV, Non-endometriotic ovarian tissue; EMS-OV, ovarian endometriotic cyst.